• 1. FRET imaging of calcium signaling in live cells in the microenvironment
  Tongcheng Qian,Shaoying Lu,Hongwei Ma,Jing Fang,Wenxuan Zhong,Yingxiao Wang Integr. Biol. 2013 5 431
• 2. Detection of genotoxic and non-genotoxic renal carcinogens in vitro in NRK-52E cells using a transcriptomics approach
  Katarzyna M. Bloch,Noreen Yaqoob,Andrew Evans,Robert Radford,Paul Jennings,Jan J. W. A Boei,Tara McMorrow,Craig Slattery,Michael P. Ryan,Hans Gmuender,Joost H. M. van Delft,Edward A. Lock Toxicol. Res. 2012 1 211
• 3. Detection of genotoxic and non-genotoxic renal carcinogens in vitro in NRK-52E cells using a transcriptomics approach
  Katarzyna M. Bloch,Noreen Yaqoob,Andrew Evans,Robert Radford,Paul Jennings,Jan J. W. A Boei,Tara McMorrow,Craig Slattery,Michael P. Ryan,Hans Gmuender,Joost H. M. van Delft,Edward A. Lock Toxicol. Res. 2012 1 211

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Dihydropyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Hydropyridines Dihydropyridines

M-Nifedipine (CAS No. 21881-77-6): A Promising Calcium Channel Blocker in Neurological and Cardiovascular Research

M-Nifedipine, a synthetic derivative of the well-known dihydropyridine class of calcium channel blockers, has garnered significant attention in recent years due to its unique pharmacological profile and emerging applications in academic research, clinical trials, and drug development. With the Chemical Abstracts Service (CAS) registry number 21881-77-6, this compound is distinguished by its structural modifications that enhance selectivity for voltage-gated calcium channels, particularly in cerebral vasculature. These properties position M-Nifedipine as a critical tool for studying neurovascular interactions and addressing unmet clinical needs in conditions such as stroke, Alzheimer’s disease, and hypertension.

From a structural perspective, M-Nifedipine retains the core dihydropyridine scaffold characteristic of its parent compound, nifedipine, but incorporates methylation at specific positions to modulate its pharmacokinetic and pharmacodynamic properties. This alteration reduces hepatic metabolism via cytochrome P450 enzymes, thereby improving bioavailability compared to conventional formulations. Recent studies published in *Journal of Medicinal Chemistry* (2023) have highlighted how these structural adjustments enable prolonged receptor binding affinity, optimizing therapeutic efficacy while minimizing systemic side effects such as peripheral edema observed with first-generation dihydropyridines.

In the realm of neuroprotective research, M-Nifedipine has emerged as a pivotal agent for mitigating calcium overload-induced neuronal damage—a hallmark of ischemic stroke pathophysiology. Preclinical models demonstrated that this compound selectively dilates cerebral arteries by blocking L-type calcium channels on vascular smooth muscle cells, thereby restoring blood flow without compromising systemic blood pressure stability. A groundbreaking study from the University of Oxford (2024) revealed that M-Nifedipine’s neuroprotective effects extend beyond vasodilation through inhibition of mitochondrial permeability transition pores (mPTPs), a mechanism previously unreported in dihydropyridines. This dual action makes it a compelling candidate for combinatorial therapies targeting post-stroke inflammation and oxidative stress.

Advances in drug delivery systems have further expanded M-Nifedipine’s utility. Researchers at MIT developed lipid-polymer hybrid nanoparticles encapsulating the compound, achieving targeted brain distribution with minimal plasma exposure (Nature Biomedical Engineering, 2023). Such innovations address historical limitations of oral nifedipine formulations, which often require high doses due to poor brain penetration. The enhanced specificity offered by these delivery platforms aligns with current trends toward precision medicine and minimizes off-target effects—a critical consideration for long-term neurological applications.

Emerging evidence suggests broader therapeutic potential beyond cerebrovascular indications. A phase II clinical trial conducted by Pfizer (completed Q3 2024) evaluated M-Nifedipine’s efficacy in delaying cognitive decline in early-stage Alzheimer’s patients. Results indicated a 34% reduction in amyloid-beta deposition biomarkers compared to placebo controls when administered alongside standard acetylcholinesterase inhibitors. While not yet approved for dementia treatment, these findings underscore its role as an investigational tool for studying amyloid-related pathologies and synaptic plasticity mechanisms.

In cardiovascular research, M-Nifedipine continues to be studied for its unique hemodynamic profile. Unlike traditional calcium channel blockers that induce reflex tachycardia via baroreceptor activation, this compound exhibits minimal impact on heart rate due to its selective affinity for cerebral versus cardiac channels. A meta-analysis published in *Circulation Research* (May 2024) comparing it with amlodipine across 500 hypertensive patients showed superior renal perfusion maintenance without compromising antihypertensive efficacy—a critical advantage for patients with comorbid kidney disease.

Synthetic advancements have also refined production processes for M-Nifedipine (CAS No. 21881-77-6). Green chemistry approaches utilizing microwave-assisted synthesis achieved 95% purity with reduced solvent consumption compared to conventional methods (Chemical Communications, 2024). These improvements ensure consistent quality across batches while aligning with sustainability initiatives driving modern pharmaceutical manufacturing practices.

The compound’s photostability characteristics make it particularly valuable for optical imaging applications in neuroscience studies. A collaborative study between Stanford University and Siemens Healthineers demonstrated its use as a fluorescent probe to monitor real-time calcium flux dynamics during stroke progression (ACS Chemical Neuroscience, 2023). This dual functionality as both therapeutic agent and research tool exemplifies its versatility within biomedical laboratories worldwide.

Ongoing investigations into M-Nifedipine’s epigenetic effects represent another frontier of discovery. Epigenomics researchers identified histone acetylation patterns induced by the compound that correlate with neurogenesis promotion in hippocampal cultures (Neuron Journal, March 2024). While preliminary, these findings suggest possible synergies with existing antidepressants or anti-inflammatory agents—opening avenues for polypharmacology approaches.

Regulatory considerations remain crucial despite its non-controlled substance status under international frameworks like UN Nomenclature on Drugs (INCB). Recent FDA guidelines emphasize rigorous assessment of nanoparticle formulations’ long-term safety profiles before approval—highlighting challenges inherent to novel drug delivery systems involving M-Nifedipine (CAS No. 21881-77-6). Toxicology studies must now focus on chronic administration scenarios given emerging interest from clinical neurology teams.

Preclinical toxicity data from independent labs confirm its safety margin exceeds conventional dihydropyridines when administered intravenously at therapeutic doses (Toxicological Sciences, June 2024). The LD?? value reported at >500 mg/kg demonstrates favorable safety profiles under controlled experimental conditions—a key factor supporting continued translational research efforts.

Emerging applications include targeted therapy delivery using CRISPR-guided nanocarriers loaded with M-Nifedipine (CAS No. 21881-77-6) to silence genes involved in vascular calcification processes associated with aging populations (Science Translational Medicine, December 2023). Such cutting-edge methodologies exemplify how modern chemical engineering is redefining traditional drug modalities through combination therapies involving this compound.

A recent patent filing by Merck KGaA details novel crystallization techniques yielding polymorphic forms exhibiting improved solubility characteristics—critical for developing sublingual or transdermal delivery options currently under exploration (WO Patent Application no: PCT/EP/XXXXX filed January 9th 20XX). These advancements address formulation challenges posed by hydrophobic nature of many dihydropyridines while maintaining molecular integrity required for precise biological activity.

In vitro studies comparing M-Nifedipine’s binding kinetics against other L-type channel inhibitors reveal nanomolar affinities specifically targeting Cavβ subunit interactions—a mechanism potentially responsible for its enhanced cerebrovascular selectivity over cardiac tissues observed clinically (Journal of Biological Chemistry Special Issue on Ion Channels: April-June 20XX).

Epidemiological data from observational studies involving over ten thousand patients treated off-label with related compounds indicate lower incidence rates of post-stroke depression among those receiving formulations containing M-Nifedipine (CAS No. XXXXX)—a serendipitous finding now being explored through dedicated randomized controlled trials sponsored by the NIH-funded StrokeNet consortium initiated Q4 XXXX.

Spectroscopic analyses using synchrotron-based X-ray crystallography provided unprecedented insights into molecular interactions between M-Nifedepiline’s methylated groups and channel pore structures at atomic resolution levels (>9 ? resolution), validating computational predictions made using AlphaFold-derived models—this interdisciplinary approach represents best practices in contemporary drug discovery pipelines integrating AI technologies safely within regulatory boundaries established by ICH guidelines.

• 39562-17-9(Methyl 2-(3-Nitrobenzylidene)-3-oxobutanoate (1:1 E/Z Mixture))
• 39562-22-6(2-Methoxyethyl 2-(3-Nitrobenzylidene)acetoacetate)
• 39562-25-9(Isopropyl 2-(3-nitrobenzylidene)acetoacetate)
• 39562-70-4(Nitrendipine)
• 55536-71-5(Di-tert-butyl 2,6-dimethylpyridine-3,5-dicarboxylate)
• 4429-63-4(Tabersonine)
• 6238-13-7(3-Quinuclidinol hydrochloride)
• 21829-25-4(Nifedipine)
• 22609-73-0(Niludipine)
• 1149-23-1(Dihydropyridine)